Takeda focuses its R&D efforts on four core therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience and Gastroenterology, with targeted investments in Plasma-Derived Therapies and Vaccines. Leveraging platform capabilities in cell therapy, gene therapy and data sciences, we’re working to deliver a steady stream of next-generation therapies with transformative or curative potential across our core areas. We're focused on targeting patient populations in areas of high unmet need.
Takeda R&D is in constant pursuit of scientific breakthroughs to deliver transformative therapies to patients worldwide. This requires a vast network of experts, an unmatched understanding of our core therapeutic areas, and world-class resources. Through partnerships, collaboration, and research, we are fostering an ecosystem of innovation to translate cutting-edge science into impactful health solutions.
We seek partners who believe our global reach, scientific expertise and clinical excellence can help them bring their vision to patients. Takeda’s Center for External Innovation takes an inclusive approach to harnessing innovation from target identification through clinical development and commercialization. Our model supports diverse and flexible approaches to partnership across the discovery and development cycle, including academic alliances, biopharma venture investing and business development partnerships for assets and technologies.
Our external mindset is focused on identifying innovations both outside and within our walls. We think differently, and creatively, about how we work with our partners and build on our combined strengths across all stages of discovery, development and commercialization.
We're open to exploring new and different ways of partnering with you. We’ve structured our partnering organization to support creative collaborations tailored to your unique needs, ranging from innovative deal structures to novel implementation models and beyond.
We deeply value your company’s expertise, skills and unique culture, and will help you leverage the benefits of teaming with Takeda: a flexible, people-oriented company; an ecosystem of academic institutions, nonprofit organizations, venture capital firms and biopharmaceutical peers; and a highly motivated alliance team with commercial expertise and a track record of success across the entire product lifecycle.
How we operate and work with partners is guided by Takeda’s core values, forged over 238 years. They are the inspiration for our spirit of collaboration and our unwavering commitment to bring better health and a brighter future to people worldwide.
As a global pharmaceutical company representing Japan and Asia and being built on a solid foundation of research and development, Takeda is committed to sharing its know-how and expertise in order to create an environment within which innovation can flourish. The success of Shonan iPark in becoming the heart of a world-class ecosystem will require efficient and effective collaboration between industry, national government, and academia, as well as local governmental, municipal, and medical institutions. Through supporting these efforts, Takeda will continue to strive for better health and a brighter future for all.
The Innovators in Science Award, proudly sponsored by Takeda and administered by the New York Academy of Sciences, was established in November 2016. It recognizes a promising Early Career Scientist and an outstanding Senior Scientist’s contributions to science in the therapeutic areas of Neuroscience, Gastroenterology, Regenerative Medicine, and Oncology. The award is intended to support their commitment to innovative research.
Two prizes of US$200,000 are awarded each year, in a specific therapeutic area: one to an Early Career Scientist and the other to a well-established Senior Scientist from around the world who have distinguished themselves for their creative thinking and impact of research.
Takeda is a proud member of the COVID R&D Alliance focused on finding treatments through shared expertise, data, and evaluation of drug candidates.
For 240 years, we’ve focused on bringing better health and a brighter future to people around the world by translating science into life-changing medicines that make a critical difference for patients. Our R&D engine has produced exciting new molecular entities (NMEs) across our core Therapeutic Areas: Oncology, Rare Genetics and Hematology, Neuroscience and Gastroenterology. In these areas, we’re focused on targeted patient populations where we’re able to deliver the greatest therapeutic benefit for patients.
Our pipeline is projected to deliver value in two distinct waves. In the near-term through FY2024, there are 11 NMEs with the potential for 15 launches, representing best-in-class or first-in-class therapies. Looking to FY2025 and beyond, our R&D engine with internal research capabilities and external partnerships is expected to deliver a steady stream of next-generation therapies that will sustain our growth. These programs leverage new platform capabilities in cell therapy, gene therapy and data sciences.
Our dedicated clinical trial website serves as a resource for patients, medical professionals, researchers, and others interested in learning about past and ongoing clinical trials. It provides information about our policies and values as we carry out clinical research and our commitment to integrity and transparency. Additionally, this site provides information about how academic researchers can access patient-level data to permit secondary research through Takeda’s policies for responsible clinical trial data sharing.
By providing access to clinical trial protocol information and summary results, we seek to provide clinical research transparency to spur scientific innovation, improve medical care, and build public trust.
